GlassScriptPhysician profile
George A Romar
NPI 1124641402
$10,213.74
in general payments reported to CMS, 2019-2025
20 companies · $6,388 in 2025
The $6,388 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $99.99 · 2022: $475 · 2023: $903 · 2024: $2,348 · 2025: $6,388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,660 · Consulting Fee: $2,304 · Travel and Lodging: $370 · Education: $306.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,659.65 |
| Consulting Fee | $2,304.00 |
| Travel and Lodging | $369.55 |
| Education | $305.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $2,813.32 | 2024-2025 | |
| Abbvie INC. | $1,816.32 | 2022-2025 | Rinvoq |
| Pfizer INC. | $664.29 | 2023-2025 | |
| Janssen Biotech, INC. | $649.62 | 2021-2025 | Tremfya, Stelara |
| Galderma Laboratories, L.P. | $628.77 | 2024-2025 | Nemluvio |
| Ucb, INC. | $606.54 | 2024-2025 | Bimzelx |
| Arcutis Biotherapeutics, INC. | $546.95 | 2023-2025 | Zoryve |
| Incyte Corporation | $528.11 | 2022-2025 | Opzelura |
| Dermavant Sciences, INC. | $323.47 | 2024 | Vtama |
| Botanix Sb INC | $225.86 | 2025 | Sofdra |
| Organon LLC | $207.28 | 2025 | Vtama |
| Regeneron Healthcare Solutions, INC. | $204.00 | 2024-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $178.94 | 2024-2025 | Sotyktu |
| Lilly USA, LLC | $162.18 | 2024-2025 | Olumiant, Ebglyss, Taltz |
| Novartis Pharmaceuticals Corporation | $148.98 | 2024-2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $146.91 | 2025 | Adbry, Anzupgo |
| Sun Pharmaceutical Industries INC. | $104.06 | 2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $102.99 | 2023-2025 | Cabtreo, Siliq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.41 | 2024 | |
| Cipher Pharmaceuticals US LLC | $56.74 | 2025 | Spinosad, Natroba |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Romar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.